Glaukos Corporation Stock News

Glaukos (NYSE:GKOS) tumbled as much as 35%, to its lowest point since August 2018, after issuing soft guidance for 2020 sales and JPMorgan downgraded its shares to Neutral from Overweight.Sees 2020 n

Fly Intel: Wall Street's top stories at midday MMM HPQ XRX DELL MSFT APT SGMO FTCH W GKOS BYND

GKOS earnings call for the period ending December 31, 2019.

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Sell rating on Glaukos (GKOS). The company's shares closed last Monday at

Glaukos Corporation (NYSE:GKOS) Q4 2019 Earnings Conference Call February 27, 2020 4:30 PM ET Company Participants Chris Lewis – Director of Investor Relations

SAN CLEMENTE, Calif. (AP) _ Glaukos Corp. (GKOS) on Thursday reported fourth-quarter net income of $36.6 million. On a per-share basis, the San Clemente, California-based company said it had net incom

SAN CLEMENTE, Calif. (AP) _ Glaukos Corp. (GKOS) on Thursday reported fourth-quarter net income of $36.6 million. On a per-share basis, the San Clemente, California-based company said it had net incom

Glaukos Corp:

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today an

The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fa

Thomas Burns became the CEO of Glaukos Corporation (NYSE:GKOS) in 2002. This analysis aims first to contrast CEO...

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma

Glaukos (NYSE:GKOS) will be announcing its earnings results after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. I

In 2002 Thomas Burns was appointed CEO of Glaukos Corporation (NYSE:GKOS). This report will, first, examine the CEO...

Biotech stocks turned in a lackadaisical performance last week amid earnings releases by smid-cap stocks, a few clinical readouts and data presentations at conferences and a handful of FDA verdicts. M